Historical Stock Chart
2 Months : From Aug 2019 to Oct 2019
By Colin Kellaher
Amgen Inc. (AMGN) on Friday said a phase 3 study evaluating its cancer drug Kyprolis in combination with dexamethasone and Johnson & Johnson's (JNJ) Darzalex compared with Kyprolis and dexamethasone alone met its primary endpoint of progression-free survival.
The Thousand Oaks, Calif., biotechnology company said the regimen resulted in a 37% reduction in the risk of progression or death in patients with relapsed or refractory multiple myeloma, a cancer that forms in a type of white blood cells called plasma cells and causes cancer cells to accumulate in the bone marrow.
Amgen said the phase 3 study confirms the benefit for patients shown in an earlier phase 1 study using the same combination, adding that it plans to discuss the data with health authorities in preparation for regulatory submissions.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
September 13, 2019 09:36 ET (13:36 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.